ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Physicians Not Giving Enough Narcotics For Effective Pain Control, M.D. Anderson Specialist Tells Seminar

April 14, 1989

FDA Approves Imaging Agent For Recurrent Prostate Cancer

September 28, 2012

Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease

June 29, 2012

FDA Approves Abraxane And Alimta for NSCLC

October 26, 2012

New Approach To Replacing Immune Cells Shrinks Tumors

September 27, 2002

Clinical Study Group Proposed To Examine Peer Review System

October 15, 1993